Paying for Mental Health Care

TMS or Spravato First? An Access-and-Cost Comparison

Save

Choosing between TMS and Spravato often turns on logistics and coverage rather than a single right answer. They differ in schedule burden and in how plans approve them, and both usually require prior authorization and prior-treatment history. The best sequence is one you set with a prescriber [1].

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What separates TMS and Spravato on schedule alone?

The time commitment is one of the clearest practical differences. TMS is typically delivered as short sessions on most weekdays across roughly a course of weeks, so the burden is frequency over time. Spravato is given in a certified setting with a monitoring window after each dose, so the burden is a longer visit on dosing days. Which pattern fits depends on your work, travel, and support at home. Reading whether you can do TMS while working full time and what a Spravato appointment involves helps you picture each schedule before committing to either.

Which one is your plan more likely to cover first?

Coverage varies by plan, and neither is reliably easier everywhere. Both usually require prior authorization and documentation that earlier treatments were tried, so the paperwork burden is real for each. Health-economics researchers have analyzed the cost and value of both esketamine and rTMS for treatment-resistant depression, which is part of why payers scrutinize them 234. The practical step is checking your own benefits before you decide. Comparing whether insurance covers TMS and whether insurance covers Spravato side by side tells you more about your real options than any general rule.

Do the eligibility criteria overlap?

They overlap a lot. Both are generally offered for depression that has not responded to earlier treatments, so plans often expect a documented history of prior antidepressant trials before approving either. There are also differences: certain conditions can make TMS inappropriate, and each has its own screening. This article does not assess which is more effective, only how the access gates compare. Reading what can disqualify you from TMS and how to qualify for Spravato shows where the criteria diverge, and your prescriber can tell you which gate you are closer to clearing.

What are the real out-of-pocket differences?

Cost structure differs as much as the price. TMS is usually billed as a course of sessions, while Spravato is billed per dosing visit, often alongside a separate charge for the monitoring time. Surveys of patients and clinicians have identified cost and access as recurring barriers to these interventional options 1. Because plan design drives the final number, general figures rarely predict your bill. Looking at what TMS costs with insurance and what Spravato costs per session against your own benefits gives a more honest estimate than any headline price.

When to decide with a prescriber

Sequencing these treatments is a clinical decision shaded by coverage, not something to settle from an article. A prescriber who knows your history can weigh which fits your schedule, which your plan will approve more readily, and which screening you already meet. This page is meant to help you ask sharper questions, not to point you toward one option. Gale can help you gather the prior-treatment documentation and run the coverage checks for both, so when you and your prescriber choose a sequence, the access side is already mapped rather than guessed.

Common questions

It depends on your plan; neither is reliably easier everywhere. Both usually require prior authorization and documentation of prior treatments. Checking your own benefits for each, rather than relying on a general rule, is the most reliable way to know.

TMS typically means short sessions on most weekdays over a course of weeks. Spravato means in-clinic dosing with a monitoring window on dosing days. The right fit depends on your work, travel, and support, so it helps to picture each before deciding.

Generally yes. Both are usually offered for depression that has not responded to earlier treatments, so plans often expect a documented history of prior antidepressant trials before approving either. Each also has its own screening criteria.

That is a clinical decision to make with a prescriber, weighing schedule, coverage, and your screening results together. This comparison is meant to help you ask better questions, not to recommend one option over the other.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

A note on this information

This article compares access and cost logistics only; it does not assess effectiveness and is not medical advice. Eligibility, coverage, and treatment choices are decisions to make with a licensed prescriber and your insurer. If you are in crisis, you can reach the 988 Suicide & Crisis Lifeline any time by calling or texting 988.

References

  1. 1.Cortright MK et al. (2024). Perceived Barriers to Using Neurostimulation: A National Survey of Psychiatrists, Patients, Caregivers, and the General Public. The Journal of ECT. doi:10.1097/YCT.0000000000000990 ✓National survey of psychiatrists, patients, caregivers, and the public on perceived barriers to neurostimulation (an access lens).
  2. 2.Agboola F et al. (2020). The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy (JMCP). doi:10.18553/jmcp.2020.26.1.16 ✓ICER evidence report on the clinical effectiveness and value (cost) of esketamine for treatment-resistant depression.
  3. 3.Ross EL & Soeteman DI (2020). Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatric Services. doi:10.1176/appi.ps.201900625 ✓Cost-effectiveness analysis of esketamine nasal spray for treatment-resistant depression in the United States.
  4. 4.Zemplényi A et al. (2022). Repetitive transcranial magnetic stimulation may be a cost-effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder. BMC Psychiatry. doi:10.1186/s12888-022-04078-9 ✓Economic evaluation examining rTMS as a possibly cost-effective alternative to antidepressants after two treatment failures.

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library